Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment.

Carol WyshamHarpreet S BajajStephano Del PratoDenise Reis FrancoArihiro KiyosueDominik DahlChunmei ZhouMolly C CarrMichael CaseLivia Firmino Gonçalvesnull null

Published in: The New England journal of medicine (2024)

In adults with type 2 diabetes who had not previously received insulin, once-weekly efsitora was noninferior to once-daily degludec in reducing glycated hemoglobin levels. (Funded by Eli Lilly; QWINT-2 ClinicalTrials.gov number, NCT05362058.).

Keyphrases

type diabetes
glycemic control
insulin resistance
cardiovascular disease
physical activity
metabolic syndrome
adipose tissue
weight loss